Search

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Jun 10 2016 Posted in Press releases

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Lighting the Flame program

Spark your interest in hematology by joining our free training program for medical students, interns, and residents who have not yet chosen a specialty.